Read original article and view video content here. Brooklyn Nets’ radio announcer Chris Carrino is being honored by the NBA for both his decades of work and the obstacles he has overcome. After more than 20 years as the radio play-by-play voice of the Nets, Carrino has been recognized by the NBA with “The Values …
Read more “Brooklyn Nets’ radio announcer Chris Carrino honored by NBA”
“The progression of FSHD can make it increasingly difficult to pursue work, hobbies, social and family life,” Mark Stone, CEO of the FSHD Society, said. “The REACH trial with losmapimod represents the first real hope for those living with the disease, their families and their caregivers, who have waited so long for a potential treatment to be found.”
EPIC BIO, a biotechnology company developing ultracompact therapies to modulate gene expression in vivo, today announced its launch and Series A financing of $55 million. Epic was founded by Stanley Qi, Ph.D., a renowned bioengineer and named co-inventor on the CRISPR patent held by the University of California. The company’s mission is to develop a new class of genetic medicines that act on the epigenome, a naturally occurring mechanism that determines which genes are expressed and at what levels.
Chip Wilson, founder of the athletic-inspired apparel company Lululemon, has committed $100 million to find a cure for his rare disease, facioscapulohumeral muscular dystrophy type 2.
A team of Florida State University researchers has found that using sophisticated gene-editing techniques, they can essentially turn off or remove part of the genetic code that leads to the disease
Fulcrum Therapeutics has announced positive results with its ReDUX4 trial for losmapimod, providing new hope for the Facioscapulohumeral muscular dystrophy (FSHD) community after decades of unsuccessful clinical trials.
CRISPR-Cas9, originally discovered in prokaryotic organisms to be part of their immune system, has rapidly developed into a gene editing tool far more accurate than its predecessors. This technology is thus generating a lot of buzz due to its potential to correct genetic diseases. However, what if it could be used to identify factors that can lessen disease severity? These targets could be the source of novel treatments. A recent study out in Science Translational Medicine led by Angela Lek PhD and Louis Kunkel PhD explored this in Facioscapulohumeral Muscular Dystrophy (FSHD), a type of muscular dystrophy for which there is no treatment or cure.
Justin Cohen is a remarkable young researcher, living with FSHD, and efforting to find a cure for the disease. The Carrino Foundation is proud to make his work possible. Here is Justin’s story, in his own words.
There are approximately 15 steps that Chris Carrino will need to navigate in order to reach his broadcast position inside Wells Fargo Center. It may not seem all that daunting, but a small flight of stairs is physically challenging and potentially dangerous for someone living with muscular dystrophy.